Filing Flows › Comparisons › MIST vs ARVN
Milestone Pharmaceuticals vs Arvinas: MIST and ARVN compared
Milestone Pharmaceuticals is the larger company: $559K of revenue in its latest quarter (Q2 2026) against $500K for Arvinas (Q3 2026).
Where the money goes: MIST and ARVN
Milestone Pharmaceuticals (MIST) · Q2 2026
Milestone Pharmaceuticals, Q2 2026: revenue $559K, net loss $28.6M, operating cash flow −$22.7M. The chart follows the revenue to costs, profit and cash.
Arvinas (ARVN) · Q3 2026
Arvinas, Q3 2026: revenue $500K (-99% year over year), net loss $53.9M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
| Milestone Pharmaceuticals (MIST) | Arvinas (ARVN) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $559K | $500K |
| Revenue growth, Y/Y | — | -99% |
| Operating margin | n/m | n/m |
| Net earnings | −$28.6M | −$53.9M |
| Operating cash flow | −$22.7M | −$10.4M |
Questions
Which is bigger, Milestone Pharmaceuticals or Arvinas?
Milestone Pharmaceuticals is the larger company: $559K of revenue in its latest quarter (Q2 2026) against $500K for Arvinas (Q3 2026).
More: Milestone Pharmaceuticals earnings · how Milestone Pharmaceuticals makes money · Arvinas earnings · how Arvinas makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.